Hantavirus comparisons
How hantavirus differs from other infectious diseases, and how hantavirus species and syndromes differ from one another.
Hantavirus vs COVID-19
How hantavirus differs from COVID-19: transmission route, lethality, symptoms, geographical reach, vaccines and pandemic potential. A side-by-side comparison.
HFRS vs HPS
Hemorrhagic fever with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) are two distinct clinical syndromes caused by different hantaviruses. Symptoms, geography, lethality and treatment compared.
Andes virus vs Sin Nombre virus
Andes and Sin Nombre are the two most-studied New World hantaviruses. Both cause hantavirus pulmonary syndrome but differ in geography, transmission and clinical patterns.
Hantavirus vs Lassa fever
Hantavirus and Lassa fever are both rodent-borne hemorrhagic fevers but differ in geography, virus family, spread and treatment. Side-by-side comparison.
Hantavirus vs influenza
Hantavirus opens with flu-like symptoms — fever, muscle aches, headache, fatigue. Three to seven days later it diverges sharply. The difference matters because timely ICU admission saves lives.
HPS vs SARS
Both diseases produce abrupt respiratory failure after a flu-like prodrome. They are caused by different virus families, transmit very differently, and have different fatality profiles, but ICU presentation can look similar.
Hantavirus vs Ebola
Hantavirus and Ebola are both hemorrhagic-capable RNA viruses, but they differ in family, vector, transmissibility and geographic burden.
Hantavirus vs Marburg
Marburg and hantavirus are both highly lethal RNA viruses but with different reservoirs (bats vs rodents), transmissibility profiles and clinical syndromes.
HPS vs other causes of ARDS
How hantavirus pulmonary syndrome differs from the more common causes of acute respiratory distress syndrome — pneumonia, sepsis, aspiration, COVID-19.
Hantavirus vaccine vs Lassa vaccine
Why neither hantavirus nor Lassa fever has a globally licensed vaccine in 2026 — research history, candidate platforms, and the funding gap behind both pipelines.